Online tool tracks COVID-19 vaccine development
May 28, 2020 -- A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University of Notre Dame Center for Research Computing.
CordenPharma to provide excipients for Moderna's vaccine candidate
May 28, 2020 -- A supplier of active pharmaceutical ingredients, CordenPharma, has inked a manufacturing agreement with Moderna. CordenPharma will manufacture large-scale volumes of Moderna's lipid excipient which will be used to manufacture Moderna's SARS-CoV-2 vaccine candidate, mRNA-1273.
MilliporeSigma, Baylor partnering on COVID-19 vaccine
May 27, 2020 -- MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership will help accelerate the vaccine candidates to phase I clinical trials.
EdiGene, Immunochina to develop CAR-T therapy
May 27, 2020 -- EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.
Ajinomoto to manufacture COVID-19 drug for Humanigen
May 27, 2020 -- Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab. The drug is being studied in a phase III clinical trial for adult patients hospitalized with COVID-19.
AbCellera raises $105M to fund antibody drug development
May 27, 2020 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity and more.
Thermo Fisher to operate new CSL biologics facility
May 27, 2020 -- Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.
Merck to acquire Themis for SARS-CoV-2 vaccine
May 26, 2020 -- Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2.
Merck, Ridgeback Bio partner on COVID-19 antiviral
May 26, 2020 -- Merck and Ridgeback Biotherapeutics announced that they have entered a collaboration to develop EIDD-2801, an orally available antiviral candidate in early clinical development for treatment of patients with COVID-19.
Novasep, Lysogene partner for gene therapy
May 26, 2020 -- Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based gene therapy drug candidate (LYS-GM101) for the treatment of GM1 gangliosidosis, a neuronopathic lysosomal storage disorder.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter